Articles by John
-
Join my Crowdrise campaign to help the MILLIONS who suffer ME/CFS
Join my Crowdrise campaign to help the MILLIONS who suffer ME/CFS
Click Here For Link ==> John Nicols' Crowdrise Campaign Sufferers need better and more science. Sufferers need The…
1 Comment
Activity
10K followers
-
John Nicols shared thisThanks Steve Gardner and the PrecisionLife team! This is a very meaningful advancement to help the cause for the 100's of millions (reflect on that number again...) who suffer these debilitating chronic diseases. This is the best application of AI / data science to date utilizing the world's best patient data available (thanks for that, DecodeME). And, great to see a for-profit enterprise get involved in the cause; we need to see more of that... The findings move the dial meaningfully on: - advancing our ability to accurately subtype within our complex disease space - accelerating the development of new cost effective diagnostics - strengthening the business case for new therapeutic clinical trials - making available substantial new data and analytics for new mechanistic scientific research Looking forward to what comes next from these insights. Solve ME/CFS Initiative will help to catalyze that for the community.John Nicols shared thisToday we announce major new findings from the most detailed genetic analysis of myalgic encephalomyelitis (ME, also known as ME/CFS) ever conducted. Our research has revealed more than 250 core genes associated with the disease, including 76 genes linked with long COVID, and uncovered dozens of drug repurposing opportunities supported by genetic biomarker tests, offering potential for faster and lower-risk routes to developing targeted treatments. 🚀 We're proud to share our latest study, now published in medRxiv, and publish the full list of SNPs and genes identified to support global research efforts. Using our AI-led combinatorial analytics platform, our team analyzed cohorts from DecodeME and UK Biobank to uncover 259 core genes strongly associated with ME and 7,555 SNPs, confirmed across three independent datasets. These findings provide the most detailed genetic map of ME to date, offering important evidence about the biological basis of the disease's wide-ranging effects on multiple body systems and offers a strong foundation for better diagnostic tests, targeted therapies and successful clinical trials. The study also identifies a partial overlap with long COVID biology, with 76 genes linked to both conditions, suggesting shared mechanisms while confirming their distinctiveness. This deeper understanding opens new avenues for targeted repurposing trials and mechanism based precision medicine approaches for millions of people living with ME and long COVID. None of this would have been possible without the thousands of people with ME who contributed their data to the DecodeME study, often while living with severe pain, fatigue and brain fog. We are deeply grateful for their generosity and commitment to advancing research. We also thank our LOCOME project partners, including Action for ME, the DecodeME team, Innovate UK, and the MRC Human Genetics Unit at the University of Edinburgh, as well as the Patient and Public Involvement representatives who helped to shape this work from start to finish. We hope the findings published today will encourage biopharma, clinical researchers, and academic groups to work together to accelerate drug repurposing studies and the development of new mechanism-based therapies for the hundreds of millions of people who's lives are affected by ME and long COVID. #MECFS #pwME #longCOVID
-
John Nicols shared thisIain Evans and Manou Davies have developed a truly disruptive platform technology - novel enzymes intersecting with cutting edge electrolyzers to enable low cost chemistry. Great job as well by John Davies and the Syniad Innovations team for having lead the capitalization of the company so effectively to date. Scaling and launching sustainable chemical products from the platform is the key Anodyne Chemistries work to be done from now! Both on our own, and under select industrial partnerships (interested? send a message…) In this, I am thrilled to join Bridie Barrett and innovator Robert Greene on the Board to steer that with Iain and Manou successfully. And to once again work alongside my longstanding collaborative partner, Jim Rekoske, this time commercializing Anodyne’s technology to penetrate a wide range of basic and specialty chemical markets. What a great opportunity for me personally as well - to bridge my first two career decades in the chemical industry with my last dozen+ years commercializing #syntheticbiology products - awesome!John Nicols shared thisWe’re delighted to share that John Nicols and Bridie Barrett have joined Anodyne's Board of Directors. Ms. Barrett has had an extensive career in investment banking and currently serves as a Partner at Brunswick Group, a global advisory firm. Mr. Nicols is the former president and CEO of Codexis, where he led the growth and transformation of Codexis into one of the leading synthetic biology companies. Speaking on the announcement, Anodyne’s CEO Iain Evans said: “We are delighted to welcome Bridie and John to Anodyne's board at such a pivotal moment in our growth. Their appointment expands the depth and capability of our board, bringing highly relevant expertise in commercial strategy, product development, operations, supply chain and finance." Read the full announcement: https://lnkd.in/drab-2hJ
-
John Nicols shared thisJohn Nicols shared thisHere’s the brutal truth: Most AI for enzyme design is a "black box" that fails at scale, and traditional synthesis routes are hitting a wall of rising costs and regulatory pressure. Companies are trapped between two imperfect options. At Zymvol Biomodeling, we’ve built the third way. We defy the status quo, succeeding where many other projects fail. We do it by replacing the black box with transparency and a deep understanding of reaction physics. Our team is coming to CPHI Frankfurt to prove it. → Our COO, Marina Cañellas Fontanilles, will give a talk on why our physics-AI combination is the future. → Industry titans John Nicols and Pierre Monsan will join me to host 1-on-1 "Enzyme Clinic" sessions. These sessions are for leaders who need to de-risk their process development and gain a competitive edge. We’ll dive into your specific case and outline a clear path to success. Send me a message to book a private session. Let's start building your solution. #CPHIFrankfurt
-
John Nicols shared thisLet's be honest: Many AI-driven enzyme pilots fail to reach commercial scale. During my 10 years leading Codexis and in the years since, I've been paying attention to the evolution of enzyme engineering — and I've seen this firsthand. The industry doesn't need another "black box" AI provider. It needs to see what’s actually happening inside the enzyme. That's why I'm so excited about what Zymvol is doing. Their physics-AI hyperrealistic modeling provides the transparency and predictive power to finally de-risk development. It’s the key to succeeding where others can’t. I'm joining Zymvol’s team, including biotech pioneer @Pierre Monsan and CEO @Maria Fátima Lucas, at CPHI Frankfurt for a limited number of 30-minute “Enzyme Clinic” sessions. These are candid, 1-on-1 discussions for professionals facing tough challenges in their chemical processes. If you’re tired of gambling away R&D resources and want to see how this works, DM me to book a slot. #Biocatalysis #ScaleUp #PharmaTech #EnzymeEngineering #CPHI #ProcessChemistry #Innovation
-
John Nicols shared thisGood summary; easy to say but hard to do. Chris Morgan is a master at helping executives put this into practice with their teams.John Nicols shared this5 Signs Of A High-Performing Team Credit to Dr. Christian Poensgen, follow him for more practical content. ------ Here's the original post: A team's success isn't just about their talent. It also takes: — Trust — Safety — Leadership — Commitment Every great team was once a group of individuals. They didn't know much about each other. They had to learn to trust each other. They had to find common ground. A great leader's job is to turn a group into a team. Want a high-performing team? 14 tips to get them there: 1. Provide growth opportunities 2. Create a safe environment 3. Offer and seek feedback 4. Encourage collaboration 5. Set clear expectations 6. Encourage innovation 7. Communicate openly 8. Celebrate small wins 9. Admit your mistakes 10. Build connections 11. Recognize efforts 12. Lead by example 13. Show empathy 14. Be transparent A high-performing team isn't built overnight. But with strong leadership, it will happen. Your team has the potential. Unlock it. ------- Follow Business Infographics to learn from the best visuals.
-
John Nicols shared thisFully aligned product-focused strategy; flawless historical execution; top notch team; derisked manufacturing at commercial scale; universal market interest and early purchases; clear pathway to profitability. It takes ALL of the above to attract capital in today's ultra-conservative Series B and beyond venture investor landscape. Congratulations Christina Smolke and the entire team at Antheia, Inc. for pulling it off. Other aspiring #syntheticbiology companies - there's your recipe... You can do it too! https://lnkd.in/eAqXBqasAntheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategy - AntheiaAntheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategy - Antheia
-
John Nicols reposted thisJohn Nicols reposted this📢 Today, World ME Day, we're proud to announce the inaugural Solve ME/CFS Catalyst Awards, launched by Solve M.E. to accelerate high-impact science at a critical time. This new funding initiative provides over $100,000 to studies already making promising strides in ME/CFS research—and helps them cross the finish line. 🔬 Dr. Akiko Iwasaki, Sterling Professor of Immunobiology at Yale School of Medicine, wins the first Catalyst Award for her study of the role of autoantibodies in ME/CFS neurological symptoms. Dr. Iwasaki was one of Time Magazine's Top 100 Most Influential People in 2024. “Our mission is to back bold researchers who are answering urgent patient needs,” said Solve President Emily Taylor. “This science is ready to move—and we’re here to make sure it does.” 🔗 Read the full announcement: https://lnkd.in/gWhnBKKx #MECFS #BiomedicalResearch #ScienceFunding #CatalystAwards #Innovation #WorldMEDay
-
John Nicols shared thisGreat news! Scientific Bioprocessing (sbi) is on its way to disrupt fermentation development! More data, more cheaply, more quickly --> deeper fermentation parameters' understanding earlier --> derisked, more robust biomanufacturing processes to scale and commercialize. Come, let's discuss at the SynBioBeta 2025 conference in San Jose, CA on May 6 - 8.John Nicols shared this🎉 Big news from our parent company, SCIENTIFIC INDUSTRIES, INC. They just secured approximately $1.6M in new funding to turbocharge sbi and level up our DOTS Platform. That means smarter shake flasks, next-gen sensors, and even more data-driven magic in the lab. 🧪✨ And coming soon: a powerful new optical pH sensor and a high-performance liquid injection system We’re not just shaking flasks—we’re shaking up the future of #bioprocessing. 💥 🔗 https://bit.ly/4cLVtLx #FundingNews #BiotechGlowUp #DOTSPlatform #ShakeFlask #BioprocessingReimagined
-
John Nicols shared thisNice article, Michael Scott Long, and great to see the enzyme development progress at bitBiome, Inc., Yuji Suzuki. But, #syntheticbiology company builders need to consider seriously the risks associated with their company's target projects: - Market: existing or new - Regulatory pathway: simple or complex - Technology: applied, developed, or neither Succeeding against just ONE of these risks is hard enough. Compounded risks across multiple of these categories in tandem is too much for an aspiring young company to bear. Biological solutions for plastics recycling bears ALL of these risk categories. My advice to SynBio company builders on this target: - Get a marquis company to bear all of your costs (revenue for you), and ensure the project advances your core platform technology (like bitBiome, Inc. has done here) - Avoid putting your own precious capital and talent to work at risk on this one. Like my quote in the article says, we need a global consortium (not a single company) to spread and bear the risks to commercialize a viable solution for this one. Target Selection is key.John Nicols shared thisWaste Not, Want Not: Synthetic Biology Helps Achieve Circular Chemistry On Earth Day, We’re Asking: What If Waste Could Power the Future? As we reflect on sustainability this Earth Day, one thing is clear: solving the climate crisis will require rethinking not just how we consume, but how we manufacture. In this new SynBioBeta Insights piece, Michael Scott Long explores how synthetic biology is helping the chemicals industry close the loop—transforming waste into valuable, renewable materials through circular chemistry. 👉 Read the full article here: https://lnkd.in/dia-2PYN The piece features insights from Dr. Jo Sadler of the The University of Edinburgh, who’s pioneering one-pot systems for converting plastic waste into bio-based chemicals. It also includes perspectives from John Nicols (former Codexis CEO and Chair of the Chemicals & Materials Track at #SynBioBeta 2025) on why legacy industrial systems resist change—and how innovation can break through. Meanwhile, Yuji Suzuki, CEO of bitBiome, Inc., explains how their AI-powered enzyme discovery platform is tackling PET plastics with precision biology. While scale-up and infrastructure remain hurdles, this article outlines a vision for a smarter, greener bioeconomy—one where biology and business converge to make waste a valuable input. On a day dedicated to protecting our planet, it’s a powerful reminder that the solutions may already be growing in our fermenters. #EarthDay #SyntheticBiology #CircularEconomy #GreenChemistry #Sustainability #Bioeconomy #AIinBiotech #IndustrialBiotech #BiotechInnovation #PlasticsRecycling
-
-
John Nicols reacted on thisJohn Nicols reacted on thisResilience was framed here not as a logistics fix, but as a manufacturing redesign. In this panel, Ola (Aleksandra) Wlodek of Constructive Bio, Christina Smolke of Antheia, Inc., Tina Boville of Aralez Bio, and moderator Julianna LeMieux of Genetic Engineering & Biotechnology News focused on how biology can shorten, simplify, and regionalize pharmaceutical supply chains. The sharpest supply-chain statistic came early: Wlodek said 80% of APIs used by the European Union or the U.S. come from two countries, China and India. Smolke argued that the problem is not only geographic concentration, but also fragmented synthesis spread across multiple manufacturers. Her case for Antheia’s platform was that many of those steps can be collapsed into a single fermentation that takes less than 10 days, rather than two or more years. Boville pushed the argument further upstream, focusing on non-canonical amino acids as enabling inputs for peptide and protein drugs. Across the panel, the common thesis was that biology adds the most value where chemistry becomes more complex: complex peptides, complex small molecules, and distributed manufacturing systems that can be repurposed by changing the strain rather than rebuilding the plant. The closing vision was not just onshoring, but flexible facilities that can switch from one critical medicine to another with the same fermentation infrastructure. #SynBioBeta #SyntheticBiology #Biotech
-
John Nicols liked thisJohn Nicols liked thisGenoa Ventures and Hawkwood Biotech framed industrial biotech investing as a visibility problem as much as a capital problem. In conversation at SynBioBeta, Jenny Rooke and Richard Kenny introduced BioAtlas, an open-source map designed to benchmark the companies, products, and markets shaping bio-based manufacturing. Kenny said the tool was built to answer questions the sector has struggled to centralize in one place: what biology can make, how large those markets are, how quickly they are growing, who is already building there, and how viable those products may be commercially. Among the examples he shared, 88% of product dollars in industrial biotech come from products that have already been on the market for 20 years, and about 15 products already have 30 or more companies pursuing them. The message for investors and operators was straightforward: better capital allocation starts with better market legibility. In that framing, BioAtlas is meant to help the industry see where competition is concentrated, where white space remains, and how long commercial success in industrial biotech actually takes. #SynBioBeta #SyntheticBiology #Biotech
-
John Nicols liked thisJohn Nicols liked thisThree members of the Due Diligence #Wolfpack on the prowl at #synbiobeta2026, looking for real value and no hype. From L-R, David Dodds, Sam Nejame, Steve Weiss. For fun, see our recent session as circle the pack around biomass technologies and projects - see https://lnkd.in/g9qjRx7S. Thanks again to SynBioBeta for a great conference.
-
John Nicols reacted on thisJohn Nicols reacted on this🎉 Celebrating a milestone: one year since the launch of Strategic Copilot (hardback & soft copy)! Thank you to everyone who shared knowledge, joined the podcast, recommended the book and supported me over the last 25 years - you have helped make this possible. A few updates: 📖The Kindle version launched last week and is now available. 🎧 The audiobook is on its way in the next 1–2 months, a much-requested addition, so watch this space. 🤝 We recently hosted an in-house strategic planning week with colleagues from the US, UK, and Middle East - a fantastic opportunity to collaborate and align across our core services (CEO & executive support, coaching, strategy & projects, and our Strategic Copilot masterclass). 💡 The masterclass, launched earlier this year, has already been delivered several times and we’re looking forward to scaling it further. 👏 The week also gave us a chance to celebrate our brilliant teammate Tigran M as he embarks on an exciting new chapter, alongside welcoming several familiar faces who joined throughout the sessions - a real reminder of the strength of our network. It’s been an incredibly rewarding journey so far, made all the more meaningful by the people who’ve been part of it along the way. If you haven’t yet, you can now grab a copy on Kindle, with the audiobook not far behind. And if you’re interested in joining a masterclass or exploring ways we can work together, I’d love to hear from you. 📸 Pictured here: the Kindle edition now live. https://lnkd.in/e3sFYYsZ
-
John Nicols reacted on thisJohn Nicols reacted on thisCEO and co-founder Dr. Christina Smolke is joining the main stage at SynBioBeta next week to discuss biology’s role in building the next generation of resilient pharma supply chains. Be sure to join Antheia, Constructive Bio, and Aralez Bio on Tuesday, May 5 at 2:25pm PT. https://bit.ly/4vPMS3P #Antheia #Biosynthesis #Biomanufacturing #PharmaSupplyChains
-
John Nicols reacted on thisJohn Nicols reacted on thisHard to believe it’s been 16 years since Mark King and I started our firm in a tiny walk-up office on Newbury Street in Boston, with our partnership now an incredible group: Peter Bak, Gregory Benning, Steve Gauldie, Vasilios M. Kofitsas, Chris Leo, and Jocelyn Serio-Miller. Since 2010, we've grown into a global, collaborative team working across sectors and stages. Three years ago, our horizons expanded further as we have been fortunate to partner and integrate our efforts with DNB Carnegie and DNB. Today, our core values continue to inspire a culture of high integrity, collaboration valued over individual success, and plain hard work, with insight-driven exacting analysis as the centerpiece of our daily work lives. Thank you to our team and to our extended teams across the life sciences and healthcare, through our dozens of deals and well over 1200 projects, for your support, your enthusiasm, your repeat engagement of us, and most of all your friendship. Happy birthday, Back Bay Life Science Advisors.
-
John Nicols liked thisJohn Nicols liked thisInterested in scaling biology and novel food ingredients from pilot to commercial reality? I’m excited to be speaking at SynBioBeta 2026 🏭 May 5 | 4:30 PM The Road to Commercial Scale: Capital and Market Demands Beyond the Pilot Plant 🥗 May 6 | 4:30 PM Programmable Nutrition: Engineering the Next Wave of Bioactive Food Molecules I’ll be joining an outstanding group of industry leaders: Per Falholt Richard Kenny Verena Kallhoff, Ph.D., MBA Cindy Groff-Vindman Vanderlei Casagrande Bellettini Alexandra Boelrijk Greg Hocking J. Casey Lippmeier Ivan R. Jaubert If you’re building, funding, or scaling the next generation of food and bio‑based ingredients, I’d love to connect there. #SynBioBeta #SynBioBeta2026 #SyntheticBiology #FoodTech #Biotech #ScaleUp #PrecisionFermentation #NovelIngredients
Experience
-
-
-
-
-
Education
-
-
-
-
Other similar profiles
Explore more posts
-
Bill Dykes
Are you scrambling to enhance your oil recovery in light of current oil prices. Do it with the right chemicals. Same processes, better chemistry, lower volumes and more cost effective. Take a look at the white paper to see why #LocusLeads. Don't continue to leave oil and money in the ground. Call or email Locus Bio-Energy today. Bdykes@locusfs.com or 281-701-3111. Crescent Energy Flywheel Energy, LLC Continental Resources E&B Natural Resources Ovintiv Apache Corporation Diamondback Energy Coterra Energy Chord Energy Magnolia Oil & Gas Permian Resources MACH Natural Resources Mewbourne Oil Company Oxy Chevron YPF Ecopetrol Ecopetrol in North America Scout Energy Partners Matador Resources Company BĀSA Resources, Inc. Brandon Arrington Devon Energy Validus Energy Camino Natural Resources ExxonMobil XTO Energy Petro-Hunt L.L.C Ring Energy, Inc. Riley Exploration Permian, Inc.
-
Laura Elena Dickey
Exciting News! 🐻 We're thrilled to announce that Kodiak has acquired Crown Carbon Reduction Technologies and US Chemical. This strategic move will enable us to expand our offerings and provide even more value to our customers across our platform. Through these acquisitions, we will be able to: - Enhance our service capabilities - Cut delivery timelines - Deliver more comprehensive solutions designed specifically for mining and energy operations We're looking forward to this new chapter and to continuing to deliver our robust product portfolio to our customers in the United States and beyond. https://lnkd.in/gV-MnYwB
4 Comments -
Sreedhar K
Partnering with the Value Gate keepers. Part 2/3 of Stakeholders Spectrum series Stakeholder Spectrum Diagnostic Control™ In highly regulated industries, A "No" from controllers is often a safety net. As leaders, we must turn it into a springboard of alignment. Yesterday in part one of the series, we discussed about silencing the noise from influencers and advisors. Today, we move to the center of the spectrum: The Controllers. The controllers are the people, who own the "Yes" or "No" - your Budget holders, Finance, Regulatory, and QA/Risk. Their "No" is not an obstruction, it is an accountability of risk assessment. The Value Gatekeeper Realities: Chemicals: The Finance Director sees price spikes in petroleum-based feedstocks and freezes working capital, halting your long-term hedging strategy, to prevent potential losses. Pharmaceuticals: The Head of Quality sees "Risk Acceptance" not as a box to check, but as a potential multi-million-dollar compliance failure. Flavor & Fragrance: Regulatory (IFRA/REACH) flags a high-performance ingredient as a risk. Without pre-vetted alternatives, your innovation dies on the desk. Do not fight the Value Gatekeepers: Co-author the risk profile with them. When you speak the language of Risk Mitigation instead of just cost savings, you stop being a cost center and start being a Risk Manager and a collaborator. Tomorrow. in concluding part 3 of the series, we shall cover: The final leap. Moving from "controlling" to "enabling," A true Enterprise Value. #StakeholderSpectrumControlPoints #ProcurementLeadership #RiskManagement #SreedharKAdvisors #Pharma #Chemicals #FlavorFragrance #Governance
-
Lisa W.
The chemical industry doesn't just move molecules; it moves the global economy. 🌍 In a sector where a 48-hour delivery delay can halt a multi-million dollar production line, "good enough" leadership isn't an option. To drive long-term commercial success in B2B chemicals, we must master the tension between industrial stability and market agility. I’ve found that three pillars define the leaders who win over decades, not just quarters: 🔹 Customer Trust (The Anchor): In an era of "greenwashing" and supply chain uncertainty, radical transparency is the only currency that matters. Trust is built through technical integrity and co-innovation, moving us from being a "vendor" to a critical partner. 🔹 Operational Consistency (The Floor): Consistency is the silent engine of growth. It’s the commitment to quality and logistics that allows our customers to sleep at night. Without a foundation of reliability, strategy is just noise. 🔹 Adapting to Volatility (The Edge): From feedstock fluctuations to shifting ESG regulations, volatility is the new baseline. Successful commercial leadership means building "elastic" models that can pivot pricing and sourcing without breaking the supply chain. The goal isn't just to survive the cycle, it’s to lead through it. To my peers in the industry: Which of these three is the biggest challenge for your team in 2026? Let’s discuss in the comments. 👇 #ChemicalIndustry #B2BManufacturing #CommercialLeadership #SupplyChainResilience #IndustrialInnovation
-
Aruna Miller
Maryland welcomes Syngene International Limited as they build their first U.S. facility in Baltimore City. The Moore-Miller administration is focused on building Maryland’s future with cutting-edge industries—fueling innovation, jobs, & growing the economy for all Marylanders. https://lnkd.in/eJkfusJg
-
Crystal G. Morrison, Ph.D.
The final chapter of my “Navigating the Maze” blog series just dropped! From identifying #growthopportunities to applying quantitative scoring to prioritize them, this series offers a structured, real-world approach for leaders in #specialtychemicals, #coatings, and #materials industries who want to make smarter strategic decisions. If you’ve ever asked “Where should we focus next?” this series is for you. Let me know your thoughts and please share with anyone navigating their own maze of opportunities. If you missed the prior articles, here are the links: ➡️ Part 1: https://lnkd.in/e4jHjRnu ➡️ Part 2: https://lnkd.in/eZVWdM22 ➡️ Part 3: https://lnkd.in/e-dtJit5 The ChemQuest Group, Inc. #ChemQuest #Strategy #MarketIntelligence #MaterialsScience #BusinessStrategy #Innovation
-
Dr. Michael Glaschke
Last week, leaders from across the chemical industry gathered at the @American Chemistry Council’s Annual Meeting in Colorado Springs. It was a valuable opportunity to hear what’s top of mind for so many organizations navigating today’s complex environment. A few #whenitreallymatters themes stood out as having the greatest potential for disruption — and therefore, the greatest potential for opportunity: 🔹 Managing macroeconomic uncertainty 🔹 Driving greater efficiency across operations 🔹 Adapting to new ways of working These topics will continue to shape the path forward for chemical companies around the world. Read more on the specific themes and what they mean for our industry below. Matthew McCauley, Vance L. Scott, Don Driggers or myself can share our insight with your in person. #ACC2025 #ChemicalIndustry #Innovation
-
Alex Hilliker
Check out our latest Beyond Clean expert series video, where we discuss Hydrogen Peroxide use in sterile processing. As with previous episodes, this one helps lay out the rationale for better understanding your environment to ensure safe and effective sterilization in hospitals using H2O2 every day to reprocess medical instruments. ChemDAQ, Inc. continues to fight for our customers to protect the people who are protecting the patient. More to come in 2026!
-
Colie Whitaker
I pulled together the attached summary after conversations with several manufacturers and shippers of chemical materials, listening to multiple industry and geopolitics podcasts, and reading reputable news sources covering the conflict and its impact on global trade. It’s a short look at how disruption in and around the Strait of Hormuz could affect chemical logistics, freight costs, and supply chains. Thanks for all the feedback from my previous post. You've inspired me to write another!
3 Comments
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content